ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0678

Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019

Patompong Ungprasert1, Sunisa Kongkiatkamon2, Ben Ponvilawan3, Nuttavut Sumransub4 and Paul Kroner5, 1Cleveland Clinic, Cleveland Heights, OH, 2Chulalongkorn University, Bangkok, Thailand, 3Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, 4University of Minnesota, Minneapolis, MN, 5Mayo Clinic, Jacksonville, FL

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Epidemiology, Health Services Research

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Little is known about inpatient epidemiology, morbidity, mortality and resource utilization of patients with antiphospholipid syndrome (APS). The purpose of this study is to describe those characteristics using a nationwide inpatient database.

Methods: Patients with APS were identified from the Nationwide Inpatient Sample (NIS), the largest inpatient database in the United States (US) that prospectively collects data of hospitalizations of over 4,000 non-federal acute care hospitals, using ICD-9 CM codes. Propensity score matching was used to create cohort of patients without APS to serve as comparator. They were matched to patients with APS using age, sex and Charlson Comorbidity Index as covariates. Data on demographics, reasons for hospitalization, length of stay, mortality, morbidity and expenditures were extracted. All analyzed data was extracted from the databases of the year 2019.

Results: The inpatient prevalence of APS was 85.4 cases per 100,000 admissions. The cohort was predominantly female (73.2%) with the mean age of 51.7 years. Comparing with propensity score-matched comparators without APS, hospitalizations among patients with APS were significantly associated with longer length of stay (1.8 more days; 95% confidence interval (CI), 1.1 – 2.5) and risk for development of acute kidney injury with odds ratio (OR) of 1.29 (95% CI, 1.10 – 1.50). Other inpatient outcomes, including inpatient mortality, shock, multiorgan failure and admission to intensive care unit were not significantly different between patients with and without APS. Hospitalizations of patients with APS were associated with higher cost as demonstrated by an additional mean of $5,300 (95% CI, $4499 – $6101) for total hospital cost and an additional mean of $20,420 (95% CI, $16535 – $24305) for total hospitalization charges when compared to patients without APS.

Conclusion: Inpatient prevalence of APS was higher than what would be expected from prevalence in general population. Hospitalizations of patients with APS were associated with longer length of stay and higher healthcare expenditures.


Disclosures: P. Ungprasert, None; S. Kongkiatkamon, None; B. Ponvilawan, None; N. Sumransub, None; P. Kroner, None.

To cite this abstract in AMA style:

Ungprasert P, Kongkiatkamon S, Ponvilawan B, Sumransub N, Kroner P. Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019 [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/inpatient-epidemiology-expenditures-and-resource-utilization-of-antiphospholipid-syndrome-national-inpatient-sample-2019/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inpatient-epidemiology-expenditures-and-resource-utilization-of-antiphospholipid-syndrome-national-inpatient-sample-2019/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology